Clearmind Medicine Initiates U.S. Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has launched a Phase I/IIa clinical trial for its novel Alcohol Use Disorder (AUD) treatment, CMND-100,...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Clearmind Medicine Inc. has launched a Phase I/IIa clinical trial for its novel Alcohol Use Disorder (AUD) treatment, CMND-100,...
Theriva Biologics announced the presentation of interim safety and pharmacokinetic data from its ongoing Phase 1b/2a clinical trial of...
Unicycive Therapeutics announced positive patient-reported outcomes from a Phase 2 trial of its oxylanthanum carbonate (OLC) drug for hyperphosphatemia...
BriaPro Therapeutics, a majority-owned subsidiary of BriaCell Therapeutics, is developing novel, high-affinity antibodies targeting B7-H3, a molecule implicated in...
Microbot Medical presented positive data from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System at the Society...
Grace Therapeutics, a late-stage biopharmaceutical company, announced positive feedback from the FDA regarding its planned New Drug Application (NDA)...
Context Therapeutics has dosed the first patient in a Phase 1 clinical trial for CT-95, a bispecific antibody targeting...
Atea Pharmaceuticals has initiated its Phase 3 C-BEYOND trial, evaluating the bemnifosbuvir and ruzasvir regimen for chronic hepatitis C...
KSQ Therapeutics has dosed the first patient in a Phase 1/2 clinical trial for KSQ-004EX, a CRISPR-engineered tumor-infiltrating lymphocyte...
Ebenbuild’s Twinhale technology, a software for creating digital lung twins, was used in a preclinical study on idiopathic pulmonary...